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Abstract
Obesity and its consequences can damage the kidney over time. However, less is known
about the impact of developing overweight/obesity during childhood on the kidney in adult-
hood and the renal impact of a superimposed acute kidney injury (AKI). This study evaluated
the effect of obesity induced by a high-fat diet initiated soon after weaning on the adult life of
mice and their response to superimposed nephrotoxic effects of cisplatin. C57BL/6 post-
weaning mice (3 weeks old) were divided into a control group (CT, n = 12) and a high-fat diet
group (HF, n = 12). After 9 weeks, animals were further divided into the following groups:
CT, CT treated with a single dose of cisplatin (CTCis, 20 mg/kg, i.p.), HF and HF treated
with cisplatin (HFCis). The HF group exhibited higher body weight gain compatible with a
moderate obesity. Obese mice presented increased visceral adiposity, hyperkalemia,
sodium retention, glomerular hyperfiltration and proteinuria, without any significant changes
in blood pressure and glycemia. AKI induced by cisplatin was exacerbated in obese animals
with a 92% reduction in the GFR versus a 31% decrease in the CTCis group; this sharp
decline resulted in severely elevated serum creatinine and urea levels. Acute tubular necro-
sis induced by cisplatin was worsened in obese mice. The HFCis group exhibited robust
systemic and intrarenal inflammation that was significantly higher than that in the CTCis
group; the HFCis group also showed a higher degree of renal oxidative stress. In conclusion,
the moderate degree of obesity induced shortly after weaning resulted in mild early renal
alterations, however, obese young animals were prone to develop a much more severe AKI
induced by cisplatin.
Introduction
The rates of adult and childhood obesity are increasing worldwide, with 41 million children
affected by overweight or obesity [1, 2]. Obesity predisposes individuals to insulin resistance,
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type 2 diabetes, dyslipidemia, hypertension, inflammation, oxidative stress, liver and renal dis-
eases during childhood or adulthood [3].
Obesity is a risk factor for the development and progression of kidney disease in both adults
and children [4, 5]. Despite the increased glomerular filtration rate (GFR) caused by obesity,
the mesangial expansion, basement membrane thickening, podocyte stress and inflammation
can lead to glomerulosclerosis and tubulointerstitial injury over time [6, 7]. Abnormal albumin
excretion and hyperfiltration have been observed in obese children and adolescents even in the
absence of diabetes [8]. Thus, obesity constitutes a risk factor for the development of chronic
kidney disease in adult individuals [9, 10]; however, less is known on the impact of the onset of
obesity early during childhood on the renal function in those respective adults.
Renal hemodynamic alterations, inflammation and oxidative stress are often observed in
obese individuals, and although these manifestations may be aggravated by many associated
factors such as hypertension and diabetes, the impact of acute kidney injury superimposed to
obese individuals is unknown.
Acute kidney injury (AKI) is a serious pathological condition triggered by many factors
including nephrotoxic drugs. Cisplatin is one of the most effective and widely used chemother-
apeutic agent for the treatment of a variety of solid tumors; however, its major side effect is
nephrotoxicity [11, 12]. Cisplatin-induced AKI involves proximal tubular injury with tubular
necrosis, oxidative stress, inflammation, and vascular injury [13]. There is also concomitant
activation of multiple proinflammatory cytokines and infiltration of inflammatory cells into
the kidney [14].
Obesity is associated with more severe AKI in hospitalized and critically ill patients, and
this association is dependent on the illness severity and obesity-associated comorbidities [15,
16]. However, the impact of the AKI superimposed to moderately obese healthy individual is
unknown.
The AKI model induced by cisplatin was chosen in this study because there is a recogniz-
able relationship between obesity and cancer [17, 18] and because after a single dose of cis-
platin, approximately one-third of the patients develop nephrotoxicity [19]. The objectives of
this study were to evaluate the consequences of obesity induced shortly after weaning on adult
systemic parameters and renal function in mice and to determine whether this model of obe-
sity predisposes mice to a more aggressive nephrotoxic response induced by cisplatin.
Material and methods
This study was approved by the Ethics Committee for use of animals at the Federal University
of São Paulo (process N˚ 7235300915). Young male (3 weeks old; post-weaning) wild type
C57BL/6 mice were purchased from the Center for the Development of Experimental Animal
Models at the Federal University of São Paulo. The animals were maintained under a 12-h
light/12-h dark cycle under constant room temperature (22±1˚C) with free access to food and
tap water. On the first day after weaning, animals were randomly divided into two experimen-
tal groups: the control group, which was fed a standard mouse diet (CT, n = 12) and the second
group that was fed a high-fat diet (HF, n = 12). The standard diet (Nuvilab, Parana, Brazil)
contained 22 g % of protein, 56 g % of carbohydrate, 4 g % of fat and 3.80 Kcal/g. The high-fat
diet (Research Diets, D12451, New Jersey, USA), contained 24 g of protein (20 kcal%), 41 g of
carbohydrate (35 kcal%), 24 g of fat (45 kcal%) and 4.73 Kcal/g. After 9 weeks under their
respective nutritional regimen, mice were fasted during 12 hr and then subjected to tail vein
blood collection for glycemia determination (Accu-Chek Performa Nano, Roche Diagnostics,
Indianapolis, USA). Systolic blood pressure was estimated by pletismography (PowerLab,
ADInstruments, Bella Vista, Australia). Food intake was estimated by measuring the food
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consumed per group of 6 mice/cage over a 24-hr period. Then, animals were further subdi-
vided as follows: control diet animals receiving vehicle (CT, n = 6); control diet animals
treated with cisplatin (CTCis, n = 6); HF diet animals receiving vehicle (HF, n = 6) and HF
diet animals treated with cisplatin (HFCis), n = 6). Either cisplatin (20 mg/kg, Sigma-Aldrich,
Missouri, USA) or vehicle (saline solution) were administered by a single intraperitoneal
injection. At 24 hr after cisplatin or vehicle administration, the animals were transferred to
metabolic cages with free access to tap water to allow for 24-hr urine collection and the deter-
mination of individual water intake. After the metabolic cage study, the animals were returned
to collective cages for an additional 48 hr. At 72 hr after cisplatin administration, the animals
were anesthetized with ketamine (70 mg/kg) and xylazine (5 mg/kg), and blood samples were
collected via cardiac puncture. Then, the animals were euthanized by cervical dislocation.
Visceral fat (mesenteric, epididymis and retroperitoneal) were removed and weighed on an
analytical balance (AX 200, Shimadzu, Tokyo, Japan) and the adiposity index was calculated
by considering the total mass of the visceral fat corrected by body mass. Both kidneys were
removed, and the right kidney was immediately frozen in liquid nitrogen and stored at −80˚C
for future use. The left kidney was immediately fixed in 10% buffered formalin for histological
analysis.
Renal function parameters
Serum and urinary creatinine and urea concentrations as well as urinary protein content were
determined by using commercial kits (Labtest, Minas Gerais, Brazil) according to the manu-
facturer instructions. Serum and urinary sodium and potassium levels were determined using
a flame photometer (B462, Micronal, São Paulo, Brazil).
Gene expression of cytokines and oxidative stress markers
Quantification of the mRNA levels of inflammatory and oxidative stress markers was per-
formed by using real-time RT-PCR. Total RNA was purified from the renal tissue using the
phenol and guanidine isothiocyanate-cesium chloride method (TRIzol, Life Technologies,
Carlsbad, CA, USA), and total amount was quantified in a spectrophotometer (NanoVue,
GE Healthcare Life Science, UK). cDNA was synthetized from 2 μg of total RNA using a mix-
ture containing 0.5 mg/ml oligo (dT), 10 mM dithiothreitol (DTT), 0.5 mM deoxynucleoside
triphosphates (Amersham Pharmacia Biotech, Uppsala, Sweden), and 200 U of reverse tran-
scriptase enzyme (SuperScript RT, ThermoScientific, USA) in the presence of 1 U DNase (Pro-
mega, Madison, USA) to eliminate genomic DNA contamination. The mRNA expression
levels were estimated using quantitative real-time PCR (QuantStudio Flex 7 Real-Time PCR
System, Applied Biosystems, Carlsbad, CA, USA). Real-time RT-PCR was performed using the
SYBR1 system (Applied Biosystems, Carlsbad, CA, USA). Primers for amplification were
designed based on GenBank sequences (Missouri, USA) for tumor necrosis factor alpha (TNF-
α), interleukin 6 (IL-6), superoxide dismutase 1 (SOD1), NADPH oxidase activating enzyme
(gp91phox) and β-actin and were synthesized by Sigma-Aldrich. The following forward and
reverse primers, respectively, were used: TNF-α (CTATGTCTCAGCCTCTTCTC and CATTTG
GGAACTTCTCATCC); IL-6 (AAGAAATGATGGATGCTACCand GAGTTTCTGTATCTCTCTG
AAG); SOD-1 (CACTCTAAGAAACATGGTGGand GATCACACGATCTTCAATGG); gp91phox
(CCTCTATGCCAACACAGTGCand ACATCTGCTGGAAGGTGGAC); β-actin (CCTCTATGCCA
ACACAGTGC and ACATCTGCTGGAAGGTGGAC).The comparative CT method (ΔΔCT) was
employed to quantify gene expression, and the relative mRNA quantification was calculated as
2ΔΔCT. The mRNA expression levels were normalized to β-actin expression, which was used as
an endogenous control.
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Serum and renal cytokines quantification
An immunoassay panel (Milliplex Mouse cytokine/chemokine, EMD Millipore, Massachu-
setts, USA) for IL-6, IL-10 and TNF-α was used to analyze the inflammatory profile in serum
and renal tissue. Kidney proteins were extracted using RIPA lysis buffer, and the protein was
quantified according to manufacturer instructions. The analysis was performed by a multiplex
detection system (Luminex 100/200, EMD Millipore, Massachusetts, USA). The results were
expressed as pg/mL for serum and pg/mg protein for renal tissue.
Lipid peroxidation in kidney
The oxidative degradation of lipids in cell membranes resulting in cell damage was estimated
by quantifying malondialdehyde. Approximately 500 μL of protein extract from the kidney
was added to 500 μL of a working solution comprising 9 g trichloroacetic acid, 0.225 g thio-
barbituric acid, 1.74 μL of hydrochloric acid and 60 mL distilled water. The mixture was
heated in a 100˚C water bath for 30 minutes followed by incubation on ice for 20 minutes,
after which the contents were centrifuged at 9.500 g for 10 minutes. The standard curve was
constructed using malondialdehyde at concentrations of 0.625, 1.25, 2.5, 5 and 10 μmol and
measured on a spectrophotometer (EON, BioTek, Vermont, USA) at 532 nm to determine
the concentration of malondialdehyde in the samples. The results were expressed as μmol/
mg protein.
Protein expression
Relative quantification of the renal proteins nephrin, podocin, glutathione peroxidase and
tubulin (used as an endogenous control) was performed by using the western blot technique.
Renal tissue was homogenized in RIPA lysis buffer (pH 8) containing 50 mM TRIS (Sigma-
Aldrich, Missouri, USA), 150 mM sodium chloride (Labsynth, São Paulo, Brazil), 1.0% NP-40
(Bio-Rad Laboratories, Hercules, CA, USA), 0.5% sodium deoxycholate (Sigma-Aldrich, Mis-
souri, USA), and 0.1% sodium dodecyl sulfate (Sigma-Aldrich, Missouri, USA) containing a
protease inhibitor cocktail (Sigma-Aldrich, Missouri, USA). Total protein was quantified by
the Lowry method using a commercial kit (Protein assay reagent, Bio-Rad Laboratories, Her-
cules, USA) according to manufacturer instructions. Protein samples (50 μg) were separated
according to size in a 12% gel via SDS-PAGE and electroblotted onto nitrocellulose mem-
branes (GE Healthcare Life Sciences, UK) that were subsequently blocked for 1 hr at room
temperature with 3% bovine serum albumin (Sigma-Aldrich, Missouri, USA) in Tris-buffered
saline containing 0.05% Tween 20 (TBST, Bio-Rad Laboratories, Hercules, USA). The mem-
brane blots were probed with the following primary antibodies overnight at 4˚C in TBST
buffer containing 3% bovine serum albumin: anti-nephrin antibody (Abcam, Cambridge,
UK), 1:200 dilution; anti-podocin antibody (Santa Cruz Biotechnology, Dallas, USA), 1:500
dilution, anti-glutathione peroxidase (Abcam, Cambridge, UK), 1:1000 dilution and anti-acet-
ylated tubulin antibody (Sigma-Aldrich, Missouri, USA), 1:30.000 dilution. Membranes were
washed three times with TBST buffer and incubated with either an anti-rabbit (GE Healthcare
Life Sciences, UK) or anti-mouse (Sigma-Aldrich, Missouri, USA) horseradish peroxidase-
conjugated secondary antibody (1:30.000 dilution in TBST containing 3% bovine serum albu-
min) for 1 hr at room temperature. The protein bands were visualized by chemiluminescence
(Alliance, UVITEC, Cambridge, UK) using a chemiluminescent reagent (Immobilon Western
HRP substrate, EMD Millipore, Massachusetts, USA). The observed bands were quantified
using UVIBAND image qualification software (UVITEC, Cambridge, UK) and expressed as a
percentage of the tubulin expression, which was used as an endogenous control.
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Morphometric analysis of the glomeruli
PAS-stained renal cortex sections were used to estimate the glomerular area. Glomerular
images were obtained using a light microscope (DM1000, Leica, Wetzlar, Germany), and only
glomeruli containing a visible vascular or urinary pole were considered for the area measure-
ments. Areas of Bowman’s capsule and the glomerular tuft were determined by using a com-
puter-assisted image analyzer (AxioVision 4.6 Carl Zeiss Microscopy, Goettingen, Alemanha).
Twenty glomeruli per slide were analyzed.
Histological analyses
Formalin-fixed left kidneys were dehydrated, embedded in paraffin blocks, cut into 4-μm
thick sections and stained with Periodic Acid Schiff (PAS).
Apoptosis detection
Apoptosis was determined by TUNEL stain (ApopTag Peroxidase Kit, EMD Millipore, Massa-
chusetts, USA), according to the manufacturer’s instructions.
Statistical analysis
The results are expressed as the mean±standard error. The data were analyzed by using Sigma-
Stat software version 3.5. Student’s t-test was used to compare the results between the CT and
HF groups. Two-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was
used to compare the effects of cisplatin in the CT and HF groups. Statistical significance was
defined as p<0.05.
Results
Post-weaning high-fat diet induced moderate degree of obesity
Animals fed a HF diet exhibited a higher body mass gain from the first week after initiating
HF diet consumption compared with CT animals (Fig 1A), and the body mass in the HF ani-
mals remained higher than that in the CT group throughout the 9-week period. The higher
body mass gain in HF mice was characterized by an increase in the visceral fat content in-
cluding mesenteric, retroperitoneal and epididymal fat, as well as an increased adiposity index
(Fig 1B).
Table 1 shows the physiological parameters of the mice after 9 weeks of nutritional support.
Food consumption by the HF animals was lower than that in animals fed with standard diet;
however, the HF animals ingested more calories than the CT group, resulting in a body mass
gain 25% higher than of animals in the CT group (p<0.05). The systolic blood pressure and
fasting glucose were similar between both groups. Water intake by HF mice was reduced com-
pared to CT animals; however, the urinary volume was unchanged.
Cisplatin induced additional visceral fat accumulation in obese mice
There was a decrease in body mass 3 days after cisplatin administration in both groups, but,
surprisingly, despite the reduction in the body mass, the HFCis group exhibited a significant
increase in the visceral fat weight (retroperitoneal and epididymal) and in the adiposity index
compared to CTCis animals (Fig 2).
Obesity and acute kidney injury
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Renal morphological changes induced by obesity and cisplatin
Kidneys from obese animals presented a well-preserved parenchyma; however, the glomeruli
often presented an increased Bowman’s capsule area (Fig 3B), an expanded Bowman’s space
(Fig 3C) with no significant alterations in the glomerular area (Fig 3A). Representative histo-
logical slide with expanded Bowman’s space is shown in Fig 3D. Obese mice presented sig-
nificant reduction in the nephrin and podocin protein expressions which was additionally
reduced by cisplatin. In contrast, cisplatin did not significantly changed both nephrin and
podocin expressions in non-obese mice (Fig 3E and 3F).
Fig 1. A: Body mass evolution in the control (CT) group fed standard chow and mice fed a high-fat (HF) diet
(n = 12/group); B: Content of visceral, mesenteric, retroperitoneal and epididymal fat as well as the adiposity
index; the values for visceral fat accumulation and adiposity index were determined in the CT and HF groups
receiving vehicle (n = 6 per group); *p<0.05 vs CT.
https://doi.org/10.1371/journal.pone.0174721.g001
Obesity and acute kidney injury
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Effects of cisplatin were more severe in obese mice
Animals receiving cisplatin ingested less food compared to non-treated animals; however, the
reduction in food consumption by obese mice was more severe, which indicated a debilitating
condition in these animals. There was a decrease in water intake by animals treated with cis-
platin in both the CT and HF groups; nevertheless, the urinary volume was not significantly
changed by cisplatin (Table 2).
As expected, cisplatin caused acute kidney injury characterized by increased serum levels of
creatinine and mainly urea; however, the accumulation of serum creatinine and urea was exac-
erbated in obese animals, which had an approximately 10-fold increase in both parameters
(Fig 4A and 4C). This result was the consequence of an impressive decline (91%) in the creati-
nine clearance in the HFCis group (Fig 4B). Obese animals presented significant proteinuria
and, despite the rapid decline in creatinine clearance, the HFCis group exhibited decreased
urinary protein excretion compared with the HF group (Fig 4D). Serum sodium remained
unchanged in all groups, however, the fractional excretion of sodium (FENa) was reduced in
obese mice which was significantly increased by cisplatin (Fig 4F). FEK was higher in the
HFCis animals compared to the CTCis animals. In spite of the significant K+ loss, serum K+
was critically elevated in the HFCis group (Fig 4G–4H).
The renal parenchyma was preserved in vehicle-treated CT and HF animals (Fig 5A). In
contrast, kidneys from the cisplatin-treated animals presented focal degenerative areas with
necrotic tubules. The presence of hyaline casts, hyaline drops, brush border loss and tubular
epithelium cell death was observed in both groups (Fig 5A), but the damage caused by cisplatin
was more pronounced in obese animals, as indicated by the extensive tubular necrosis and
areas with tissue disorganization. TUNEL technique estimating apoptosis is shown in Fig 5B.
Apoptosis was detected in CT and HF animals treated with cisplatin (showed by arrows), how-
ever, the labelling was also detected in great extensions of necrotic areas, mainly in obese ani-
mals receiving cisplatin, hindering the visualization and quantification of apoptotic cells.
Obesity was characterized by mild renal oxidative stress and systemic
inflammation, which were potentiated by cisplatin
Kidneys from obese animals presented a mild degree of oxidative stress as evidenced by an
increase in the mRNA expression levels of gp91phox, a pro-oxidant enzyme, with no changes
in the intrarenal levels of malondialdehyde (lipid peroxidation), of SOD1 mRNA expression
Table 1. Physiological parameters.
Parameter CT HF
(n = 12) (n = 12)
Food Intake (g/day) 3.35±0.01 2.64±0.02*
Calorie intake (kcal/day) 11.83±0.01 12.58±0.09*
Body mass Gain (g) 12,70±0,55 16,08±1,20*
Systolic Blood Pressure (mmHg) 112±6.69 112±4.72
Fasting Serum glucose (mg/dL) 103±4.42 112±6.18
Water Intake (mL/day) 5.81±0.02 4.18±0.02*
Urinary Volume (mL/day) 1.56±0.25 2.03±0.48
Physiological parameters measured 9 weeks after nutrition support. Food intake per each animal was
estimated by measuring the food consumption during 24 hr by a group of 6 animals. Serum glucose was
measured after 12 hr fasting. Water intake and urinary volume were obtained in individual metabolic cage.
p<0.05: *vs CT.
https://doi.org/10.1371/journal.pone.0174721.t001
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levels or in the glutathione peroxidase protein levels (Fig 6A–6E). Surprisingly, none of the
oxidative stress markers evaluated in the preset study was modified by cisplatin in CT group,
however, all of them were significantly changed in obese animals receiving cisplatin.
HF diet animals presented signs of systemic inflammation with increased serum levels of
the proinflammatory cytokines IL-6 (65%) and TNF-α (28%) with decreased levels of the anti-
inflammatory cytokine IL-10 (60%). Although these changes were not statistically significant,
they may have a biological relevance and thus these results were numerically presented in
Table 3 and in Fig 7 together with cisplatin treated groups. The inflammatory markers IL-6,
TNF-α, and IL-10 in renal tissue were unchanged in the HF animals (Table 3).
Fig 7 shows the effects of cisplatin on systemic and renal inflammation markers. The effects
of cisplatin were discrete on systemic inflammation in CT animals, but a significant rise in the
renal content of TNF- α mRNA (Fig 7H). In contrast, there was an overreaction in obese ani-
mals to cisplatin with impressive increases in the serum levels of IL-6 (400-fold) and TNF-α
(40-fold). Serum IL-10 was also significantly elevated in the HFCis group (Fig 7A–7C). A simi-
lar inflammatory profile was observed in the renal tissue of the HFCis group, with higher levels
of IL-6 and TNF-α proteins (Fig 7D and 7E) and gene expression (Fig 7G and 7H). In contrast
to the systemic levels, the levels of intrarenal IL-10 were reduced in the HFCis group compared
with the CTCis group (Fig 7F), contributing to renal inflammation.
Discussion
It is well established that obesity is considered to be an independent risk factor for kidney dis-
ease, even in the absence of diabetes or hypertension [8] and the renal changes observed in the
present study suggest that a moderate degree of obesity imposed during childhood may predis-
pose these individuals to precociously develop some degree of renal dysfunction during adult-
hood. Moreover, the superimposed injury induced by cisplatin caused an overreaction of the
Fig 2. Body mass, visceral fat weight and adiposity index obtained 3 days after cisplatin or saline
administration. The data are expressed as the mean ± SEM, n = 6 per group. *p<0.05.
https://doi.org/10.1371/journal.pone.0174721.g002
Obesity and acute kidney injury
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Fig 3. Morphometric analysis of the glomeruli. A: glomerular tuft area; B: Bowman’s capsule area; C: Bowman’s space area; D: representative
PAS-stained cortex showing details of the Bowman’s space expansion in the HF and HFCis groups (arrows), 40x magnification, bar = 100 μm; E and
F: podocin and nephrin protein expression levels with the respective representative western blotting membranes (n = 6 form each group). The data of
morphometric analysis are expressed as the mean ± SEM, n = 4 per group, *p<0.05.
https://doi.org/10.1371/journal.pone.0174721.g003
Obesity and acute kidney injury
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obese mice compared with non-obese animals resulting in devastating systemic and renal
effects.
To understand the exacerbated effect of cisplatin in obese mice, is important to observe the
systemic and renal responses evoked by the obesity induced during the childhood. Animals
fed a HF diet within the first week after weaning presented visceral fat accumulation with
higher body mass gain compared to animals fed a standard diet. The body mass gain was com-
patible to a moderate degree of obesity based on the criteria considered for rodents [20–22].
HF animals presented neither diabetes nor hypertension and only a mild elevation in the
proinflammatory cytokines IL-6 and TNF-α in serum, that, in spite of non-significant may be
indicative of ongoing systemic inflammation process.
In spite of these discrete systemic alterations, obese mice presented many of the renal mani-
festations related to obesity, including the glomerular hyperfiltration, sodium retention and
expansion of Bowman’s space. The hyperfiltration was observed in the absence of the typical
obesity-related glomerular hypertrophy [23–25]. The reduction in the FENa may have contrib-
uted to the increased renal blood flow and the subsequent increase in the glomerular filtration
rate. Expansion of Bowman’s space is often observed in the kidneys of obese animals [25–27]
and it is probably related to the marked glomerular hyperfiltration [26]. In spite of the absence
of histologically evident glomerulopathy, obese mice presented proteinuria, an important sign
of glomerular injury. Podocyte dysfunction is related to proteinuria in obese patients [28] and
mice [25]. Accordingly, we found a downregulation of nephrin and podocin expressions in
obese mice kidneys that certainly contributed to podocyte injury and to proteinuria. Despite
the lack of renal inflammation, kidneys from obese mice showed signs of oxidative stress char-
acterized by an upregulation of gp91phox, that in turn, may have to contributed to suppress
the nephrin gene [29, 30] in the present model of obesity.
The deleterious renal effects of cisplatin are well known, however, the AKI induced by this
chemotherapeutic agent was much more severe in obese animals. This result is relevant con-
sidering the strong relationship between cancer and obesity [17, 18] and suggests that obese
patients can be more sensible to the nephrotoxic effects of cisplatin. In fact, obese mice pre-
sented visible signs of illness such as lethargy and inability to eat compared with non-obese
animals. Thus we decided to evaluate and euthanize animals 72 hr after cisplatin, although the
peak of cisplatin-induced renal injury in mice and rats occurs 96 hr after cisplatin administra-
tion [31]. While the obese mice presented very severe renal inflammation, oxidative stress and
AKI, non-obese animals showed lower degree of inflammation and oxidative stress, probable
due to the shorter period of evaluation. After 72 hr, the glomerular filtration rate decreased by
31% in the CTCis group and, in spite of non-significant, it resulted in a significant urea accu-
mulation. In contrast, an impressive decline of 92% in the creatinine clearance was observed in
the HFCis group, resulting in exaggerated serum creatinine and urea accumulation in obese
animals. These results clearly show a higher susceptibility of the obese mice to develop more
severe AKI compared to non-obese animals.
Table 2. Physiological parameters after cisplatin administration.
Parameter CT CTCis HF HFCis
(n = 6) (n = 6) (n = 6) (n = 6)
Water Intake (mL/day) 5.81±0.01 2.17±0.65* 4.18±0.02* 2.00±0.52&
Urinary Volume (mL/day) 1.56±0.25 1.44±0.19 2.03±0.48 1.28±0.10
Food Intake (g/day) 3.35±0.01 1.93±0.01* 2.64±0.01* 0.13±0.01#,&
Parameters were obtained in metabolic cage 24 hr after cisplatin or saline administration. p<0.05: * vs CT; # vs CTCis; & vs HF
https://doi.org/10.1371/journal.pone.0174721.t002
Obesity and acute kidney injury
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Vascular and proximal tubular injury play a major role in cisplatin-induced nephrotoxicity
[13]. Indeed, the cisplatin-induced tubular damage leading to apoptosis and acute tubular
necrosis was found in CTCis mice, however, both cell death mechanisms were also exacerbated
in obese animals, that presented extensive tubular cell death resulting in excessive loss of
sodium and potassium in the urine. Despite the increased potassium excretion, obese animals
Fig 4. Renal function parameters. Serum levels of creatinine (A) and urea (C); B: creatinine clearance; D:
urinary excretion of protein; E: serum sodium; F: fractional excretion of sodium; G: serum potassium; H:
fractional excretion of potassium. The CT and HF groups received cisplatin vehicle or saline. The data are
expressed as the mean ± SEM, n = 4–6 per group, *p<0.05.
https://doi.org/10.1371/journal.pone.0174721.g004
Obesity and acute kidney injury
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presented sublethal hyperkalemia probably because of glomeruli with minimal filtration
capabilities.
Oxidative stress and renal tissue inflammation are associated with cisplatin-induced neph-
rotoxicity [32, 33]. Although non-obese mice presented discrete alterations in the markers of
inflammation and oxidative stress in response to cisplatin, obese animals were much more
Fig 5. Tubular cell death analysis. A: Representative images of PAS-stained kidney sections. The CT and
HF slides show the integrity of the renal parenchyma with a preserved border brush (triangle). The CTCis and
HFCis animals exhibited degeneration and areas and necrotic cells characterized by hyaline casts (star),
hyaline drops (thin arrow), brush border loss (large arrow) and disorganization of the tubular epithelium
(asterisk). B: Representative images of TUNEL labelling characterizing apoptosis. 40x magnification and
bars = 100 μm.
https://doi.org/10.1371/journal.pone.0174721.g005
Obesity and acute kidney injury
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susceptible. Together with the greater intrarenal inflammation, obese mice presented a severe
profile of systemic inflammation characterized by a vigorous elevation in the circulating levels
of IL-6 and TNF-α. Interestingly, obese mice showed a rise in the anti-inflammatory IL-10,
probably as a response to compensate the exaggerated release if IL-6 and TNF-α, but this
hypothesis needs to be investigated. Thus, the presence of obesity caused an exaggerated
inflammatory response to cisplatin challenge with a heightened oxidative stress, resulting in
major organ damage. The presence of baseline low levels of systemic inflammation in obese
animals may contribute to the overreaction to cisplatin, which was probably mediated by a
sensitization mechanism. Moreover, the extensive degree of cell death observed in the obese
kidneys certainly contributed to the increased renal inflammation developed by obese mice
and thus for the rapid deterioration of renal function and more sever AKI after cisplatin
administration.
Obese mice presented an increase in visceral fat mass after cisplatin injection, and the
expansion of adipose tissue could contribute to systemic inflammation profile. The increase in
visceral fat accumulation after cisplatin administration is an intriguing observation, but this
phenomenon has also been detected in patients with testicular cancer shortly after administra-
tion of cisplatin-based chemotherapy, with an increase in liver triglyceride content mainly
Fig 6. Renal expression of oxidative stress markers. A: Malondialdehyde, a marker of lipid peroxidation,
was quantified by ELISA; B and C: the gene expression levels of the NADPH system enzyme gp91phox and
the antioxidant enzyme SOD1 were determined by real-time RT-PCR. The mRNA levels were normalized to
β-actin expression and quantified using the 2ΔΔCT method. D-E: Representative western blot and densitometry
analysis of glutathione peroxidase expression. The data are expressed as the mean ± SEM, n = 3–6 per group.
*p<0.05.
https://doi.org/10.1371/journal.pone.0174721.g006
Table 3. Inflammation markers.
Parameters CT HF
(n = 6) (n = 6)
IL-6 (pg/mL) 1.66±0.40 2.75±1.27
Serum IL-10 (pg/mL) 1.38±0.75 0.56±0.05
TNF-α (pg/mL) 1.44±0.04 1.84±0.25
IL-6 (pg/mg protein) 5.30±0.82 5.20±0.36
Kidney IL-10 (pg/mg protein) 11.01±1.28 9.45±0.60
TNF-α (pg/mg protein) 0.49±0.09 0.55±0.07
Parameters were measured in serum and in renal tissue obtained from CT and HF animals receiving vehicle.
https://doi.org/10.1371/journal.pone.0174721.t003
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observed in obese patients [34]. Currently, there is no explanation for the adiposity expansion
after cisplatin treatment, but based on the literature data, we speculate that aldosterone could
play a role in this behavior since 1) adipose tissue expresses mineralocorticoid receptors [35,
36]; 2) aldosterone induces adipogenesis [37, 38] and 3) cisplatin is able to increase aldosterone
levels [39, 40].
In summary, the results showed that this model of high-fat diet consumption in post-
weaned mice induced a moderate degree of obesity that was characterized by low-grade of sys-
temic inflammation with glomerular hyperfiltration. The renal changes found in the young
obese mice suggest that the development of mild obesity during childhood may predispose
these individuals to precociously developing some degree of renal dysfunction in adulthood.
Obese mice presented a greater susceptibility to the toxic effects of cisplatin and developed
more severe AKI than the non-obese mice, which was mediated by an exaggerated systemic
and renal inflammatory response. In conclusion, obesity predisposed young adult mice to
develop much more severe acute kidney injury induced by cisplatin.
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